Good response of linear scleroderma in a child to ciclosporin [15]

British Journal of Dermatology

Volumn 150, Issue 4, 2004, Pages 790-792

  Strauss, R M ^a   Bhushan, M ^b   Goodfield, M J D ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; CYCLOSPORIN A;

CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; LETTER; PRIORITY JOURNAL; SCHOOL CHILD; SCLERODERMA; TREATMENT FAILURE; TREATMENT OUTCOME;

CHILD; CYCLOSPORINE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; SCLERODERMA, LOCALIZED; THIGH; TREATMENT OUTCOME;

EID: 2342526603     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0007-0963.2004.05901.x     Document Type: Letter

References (11)

1. Krieg T, Meurer M. Systemic scleroderma: clinical and pathological aspects. J Am Acad Dermatol 1988; 18: 457-81.
2. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002; 138: 99-105.
3. Kornreich HK, King KK, Bernstein BH et al. Scleroderma in childhood. Arthritis Rheum 1977; 20: 343-50.
4. Kerscher M, Volkenandt M, Gruss C et al. Low-dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 1998; 38: 21-6.
5. Uziel Y, Feldman BM, Krafchik BR et al. Methotrezate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000; 136: 91-5.
6. Wörle B, Hein R, Krieg T et al. Ciclosporin in localized and systemic scleroderma - a clinical study. Dermatologica 1990; 181: 215-20.
7. Peter RU, Ruzicka T, Eckhert F. Low-dose cyclosporine A in the treatment of disabling morphea. Arch Dermatol 1991; 127: 1420-1.
8. Clements PJ, Lachenbruch PA, Sterz M et al. Cyclosporine in systemic sclerosis. Arthritis Rheum 1993; 36: 75-83.
9. Needelman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumour-necrosis-factor-α and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1992; 35: 67-72.
10. Bendtzen K, Petersen J. Effect of cyclosporin A (Cy A) on the immune response. Cy A competitively inhibits the function of monocyte/macrophage- derived T-lymphocyte-activating factor(s). Immunol Lett 1982; 5: 331-6.
11. Harper JI, Ahmed I, Barclay G et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142: 52-8.